Sixiang Shi1, Hakan Orbay2, Yunan Yang2, Stephen A Graves3, Tapas R Nayak2, Hao Hong2, Reinier Hernandez3, Haiming Luo2, Shreya Goel1, Charles P Theuer4, Robert J Nickles3, Weibo Cai5. 1. Materials Science Program, University of Wisconsin-Madison, Madison, Wisconsin. 2. Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin. 3. Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin. 4. TRACON Pharmaceuticals, Inc., San Diego, California; and. 5. Materials Science Program, University of Wisconsin-Madison, Madison, Wisconsin Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin University of Wisconsin Carbone Cancer Center, Madison, Wisconsin wcai@uwhealth.org.
Abstract
UNLABELLED: The critical challenge in abdominal aortic aneurysm (AAA) research is the accurate diagnosis and assessment of AAA progression. Angiogenesis is a pathologic hallmark of AAA, and CD105 is highly expressed on newly formed vessels. Our goal was to use (64)Cu-labeled anti-CD105 antibody Fab fragment for noninvasive assessment of angiogenesis in the aortic wall in a murine model of AAA. METHODS: Fab fragment of TRC105, a mAb that specifically binds to CD105, was generated by enzymatic papain digestion and conjugated to NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) for (64)Cu labeling. The binding affinity/specificity of NOTA-TRC105-Fab was evaluated by flow cytometry and various ex vivo studies. BALB/c mice were anesthetized and treated with calcium phosphate to induce AAA and underwent weekly PET scans using (64)Cu-NOTA-TRC105-Fab. Biodistribution and autoradiography studies were also performed to confirm the accuracy of PET results. RESULTS: NOTA-TRC105-Fab exhibited high purity and specifically bound to CD105 in vitro. Uptake of (64)Cu-NOTA-TRC105-Fab increased from a control level of 3.4 ± 0.1 to 9.5 ± 0.4 percentage injected dose per gram (%ID/g) at 6 h after injection on day 5 and decreased to 7.2 ± 1.4 %ID/g on day 12, which correlated well with biodistribution and autoradiography studies (i.e., much higher tracer uptake in AAA than normal aorta). Of note, enhanced AAA contrast was achieved, due to the minimal background in the abdominal area of mice. Degradation of elastic fibers and highly expressed CD105 were observed in ex vivo studies. CONCLUSION: (64)Cu-NOTA-TRC105-Fab cleared rapidly through the kidneys, which enabled noninvasive PET imaging of the aorta with enhanced contrast and showed increased angiogenesis (CD105 expression) during AAA. (64)Cu-NOTA-TRC105-Fab PET may potentially be used for future diagnosis and prognosis of AAA.
UNLABELLED: The critical challenge in abdominal aortic aneurysm (AAA) research is the accurate diagnosis and assessment of AAA progression. Angiogenesis is a pathologic hallmark of AAA, and CD105 is highly expressed on newly formed vessels. Our goal was to use (64)Cu-labeled anti-CD105 antibody Fab fragment for noninvasive assessment of angiogenesis in the aortic wall in a murine model of AAA. METHODS:Fab fragment of TRC105, a mAb that specifically binds to CD105, was generated by enzymatic papain digestion and conjugated to NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) for (64)Cu labeling. The binding affinity/specificity of NOTA-TRC105-Fab was evaluated by flow cytometry and various ex vivo studies. BALB/c mice were anesthetized and treated with calcium phosphate to induce AAA and underwent weekly PET scans using (64)Cu-NOTA-TRC105-Fab. Biodistribution and autoradiography studies were also performed to confirm the accuracy of PET results. RESULTS:NOTA-TRC105-Fab exhibited high purity and specifically bound to CD105 in vitro. Uptake of (64)Cu-NOTA-TRC105-Fab increased from a control level of 3.4 ± 0.1 to 9.5 ± 0.4 percentage injected dose per gram (%ID/g) at 6 h after injection on day 5 and decreased to 7.2 ± 1.4 %ID/g on day 12, which correlated well with biodistribution and autoradiography studies (i.e., much higher tracer uptake in AAA than normal aorta). Of note, enhanced AAA contrast was achieved, due to the minimal background in the abdominal area of mice. Degradation of elastic fibers and highly expressed CD105 were observed in ex vivo studies. CONCLUSION: (64)Cu-NOTA-TRC105-Fab cleared rapidly through the kidneys, which enabled noninvasive PET imaging of the aorta with enhanced contrast and showed increased angiogenesis (CD105 expression) during AAA. (64)Cu-NOTA-TRC105-FabPET may potentially be used for future diagnosis and prognosis of AAA.
Authors: Mark D Wilkinson; Edwin Szeto; Michael J Fulham; Chris J Constable; Brian C McCaughan Journal: Clin Nucl Med Date: 2003-02 Impact factor: 7.794
Authors: Yin Zhang; Hao Hong; Gregory W Severin; Jonathan W Engle; Yunan Yang; Shreya Goel; Alex J Nathanson; Glenn Liu; Robert J Nickles; Bryan R Leigh; Todd E Barnhart; Weibo Cai Journal: Am J Transl Res Date: 2012-07-27 Impact factor: 4.060
Authors: Hao Hong; Yunan Yang; Yin Zhang; Jonathan W Engle; Todd E Barnhart; Robert J Nickles; Bryan R Leigh; Weibo Cai Journal: Eur J Nucl Med Mol Imaging Date: 2011-03-04 Impact factor: 9.236
Authors: Matthias Nahrendorf; Edmund Keliher; Brett Marinelli; Florian Leuschner; Clinton S Robbins; Robert E Gerszten; Mikael J Pittet; Filip K Swirski; Ralph Weissleder Journal: Arterioscler Thromb Vasc Biol Date: 2011-01-20 Impact factor: 8.311
Authors: Hao Hong; Kai Yang; Yin Zhang; Jonathan W Engle; Liangzhu Feng; Yunan Yang; Tapas R Nayak; Shreya Goel; Jero Bean; Charles P Theuer; Todd E Barnhart; Zhuang Liu; Weibo Cai Journal: ACS Nano Date: 2012-02-16 Impact factor: 15.881
Authors: Hao Hong; Yin Zhang; Gregory W Severin; Yunan Yang; Jonathan W Engle; Gang Niu; Robert J Nickles; Xiaoyuan Chen; Bryan R Leigh; Todd E Barnhart; Weibo Cai Journal: Mol Pharm Date: 2012-07-19 Impact factor: 4.939
Authors: Sixiang Shi; Tingting Li; Xiaofei Wen; Sherry Y Wu; Chiyi Xiong; Jun Zhao; Victor R Lincha; Diana S Chow; Yiyao Liu; Anil K Sood; Chun Li Journal: Bioconjug Chem Date: 2019-09-27 Impact factor: 4.774
Authors: Hyung-Jun Im; Christopher G England; Liangzhu Feng; Stephen A Graves; Reinier Hernandez; Robert J Nickles; Zhuang Liu; Dong Soo Lee; Steve Y Cho; Weibo Cai Journal: ACS Appl Mater Interfaces Date: 2016-07-07 Impact factor: 9.229
Authors: Bai Liu; Lin Kong; Kaiping Han; Hao Hong; Warren D Marcus; Xiaoyue Chen; Emily K Jeng; Sarah Alter; Xiaoyun Zhu; Mark P Rubinstein; Sixiang Shi; Peter R Rhode; Weibo Cai; Hing C Wong Journal: J Biol Chem Date: 2016-09-20 Impact factor: 5.157
Authors: Haiming Luo; Christopher G England; Sixiang Shi; Stephen A Graves; Reinier Hernandez; Bai Liu; Charles P Theuer; Hing C Wong; Robert J Nickles; Weibo Cai Journal: Clin Cancer Res Date: 2016-03-29 Impact factor: 12.531
Authors: Christopher G England; Hyung-Jun Im; Liangzhu Feng; Feng Chen; Stephen A Graves; Reinier Hernandez; Hakan Orbay; Cheng Xu; Steve Y Cho; Robert J Nickles; Zhuang Liu; Dong Soo Lee; Weibo Cai Journal: Biomaterials Date: 2016-05-21 Impact factor: 12.479
Authors: Vincent Q Sier; Joost R van der Vorst; Paul H A Quax; Margreet R de Vries; Elham Zonoobi; Alexander L Vahrmeijer; Ilona A Dekkers; Lioe-Fee de Geus-Oei; Anke M Smits; Weibo Cai; Cornelis F M Sier; Marie José T H Goumans; Lukas J A C Hawinkels Journal: Int J Mol Sci Date: 2021-04-30 Impact factor: 5.923